Risk of primary infection and reinfection with respiratory syncytial virus.

By Glezen Wp, L. Taber, A. Frank, Kasel Ja. 1986

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus (2019, background): “RSV infection is extremely common, occurring in nearly all humans by the age of three and recurring throughout life (Glezen et al., 1986).”
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention (2012, background): “In human, high titers of serum neutralizing antibodies correlate with protection of adult volunteers against a hRSV challenge (9), and lower risk of hRSV infection in children (10) and the elderly (11).”
Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses (2016, background): “against hRSV is conferred mainly by neutralizing antibodies: (i) passive transfer of this type of antibody protects mice (9) and cotton rats (10) against a hRSV challenge; (ii) infants at high risk of severe hRSV disease can be protected, at least partially, by prophylactic administration of neutral”
Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. (1998, background): “In a subsequent study, the same investigators showed that the risk of reinfection with RSV was inversely related to the level of neutralizing antibody [10].”